BACKGROUND: Risk stratification of newly diagnosed patients with mantle cell lymphoma (MCL) primarily is based on the MCL International Prognostic Index (MIPI) and Ki-67 proliferative index. Single-center studies have reported inferior outcomes in patients with a complex karyotype (CK), but this remains an area of controversy. METHODS: The authors retrospectively reviewed 483 patients from 5 academic centers in the United States and described the effect of a CK on survival outcomes in individuals with MCL. RESULTS: A CK was found to be associated with inferior overall survival (OS) (4.5 vs 11.6 years; P<.01) and progression-free survival (PFS) (1.9 vs 4.4 years; P<.01). In patients who underwent high-intensity induction followed by autologous stem cell transplantation (ASCT) in first remission, a CK was associated with poor OS (5.1 vs 11.6 years; P 5 .04) and PFS (3.6 vs 7.8 years; P<.01). Among patients with a CK, high-intensity induction had no effect on OS (4.5 vs 3.8 years; P 5 .77) nor PFS (2.3 vs 1.5 years; P 5 .46). Similarly, ASCT in first remission did not improve PFS (3.5 vs 1.2 years; P 5 .12) nor OS (5.1 vs 4.0 years; P 5 .27). On multivariable analyses with Ki-67 and MIPI, only CK was found to be predictive of OS (hazard ratio [HR], 1.98; 95% confidence interval [95% CI], 1.12-3.49 [P 5
INTRODUCTION
Risk stratification of patients newly diagnosed with mantle cell lymphoma (MCL) has not routinely informed clinical practice and has been applied inconsistently despite the fact that the initial clinical presentation can range from indolent disease, which can potentially be observed, to very aggressive behavior, which commonly is managed with intensive therapy. 1, 2 The MCL International Prognostic Index (MIPI) uses baseline laboratory and clinical features to distinguish highrisk, intermediate-risk, and low-risk patients, and this distinction has been associated with differences in overall survival (OS) in several series. [3] [4] [5] However, in more recent analyses, the difference between the low-risk and intermediate-risk groups has become less apparent. 4 The European MCL Network recently described a modified combination of MIPI and Ki-67 (MIPI-C) that defined 4 risk groups. In this series, the 5-year OS rate ranged from 17% for the highest-risk patients to 85% for low-risk patients. 6 Other biologically based prognostic markers such as SRY-box 11 (SOX11), p53, and miR18b have been investigated, but to our knowledge are not often used in routine clinical practice.
Cytogenetics are used in several hematologic malignancies to predict outcome but have been evaluated on a more limited basis in patients with MCL. In smaller series, both a complex karyotype (CK; 3 chromosomal abnormalities) and specific cytogenetic abnormalities such as del(17p) have been associated with inferior outcomes in the eras before and after rituximab. [9] [10] [11] [12] In the prerituximab era, increasing karyotypic complexity in a small cohort of patients was found to have an adverse effect on survival in patients with MCL, 10 and this later also was observed in larger cohorts after treatment with rituximab. 13 In a single-institution study of 80 patients treated between 2002 and 2011, a CK resulted in a decreased 2-year progression-free survival (PFS) estimate of 48% compared with 70% in patients with a non-CK (P 5 .02), and a CK also was found to be associated with inferior 2-year OS (58% vs 85%; P 5 .02). However, this difference was not found to be significant when controlling for other variables such as MIPI on multivariable analysis. 11 Espinet et al also found that the degree of karyotypic complexity did not predict OS in a series of 145 patients with untreated and/or recurrent MCL, and that survival was influenced more by the specific cytogenetic abnormalities including del(17p) and add(3q). 9 Given these findings, we conducted a multi-institutional retrospective study to evaluate the effect of a CK and individual abnormalities on prognosis and outcomes in individuals with MCL.
MATERIALS AND METHODS
Patients aged 18 years with previously untreated MCL who were diagnosed between 1993 and 2015 and evaluated at 5 academic centers were eligible. Patients without survival follow-up were excluded from the analysis. We collected data for each patient, including demographic, laboratory, pathologic, and treatment-related variables of interest. Specific cytogenetic abnormalities also were collected from conventional metaphase karyotyping. This project was approved by the institutional review board at all participating sites with waiver of informed consent.
With the assistance of a clinical cytogeneticist, the full karyotypes were analyzed with aberrations such as derivative chromosomes and isochromosomes categorized into specific abnormalities for statistical analysis. We analyzed the 11 most common cytogenetic abnormalities (10 individual autosome abnormalities plus sex chromosome loss). A CK was defined as having 3 unrelated cytogenetic abnormalities not including t (11;14) , based on a conventional karyotype exclusive of fluorescence in situ hybridization, singlenucleotide polymorphism array, or other genomic assessments. We assessed for differences between patients with CK and without CK with regard to clinical presentation, baseline prognostic factors, and therapy. Staging was based on the Lugano Classification.
Statistical Analysis
Categorical variables were compared across CK status using the chi-square test or Fisher exact test when appropriate, and numeric variables were compared using analysis of variance. We also evaluated associations between CK and other prognostic markers in MCL, including MIPI and the Ki-67 proliferative index (using a cutoff value of 30% to define high Ki-67). Therapy received was evaluated by individual regimen as well as grouped as intensive versus nonintensive based on whether an induction regimen incorporated high-dose cytarabine. OS was calculated from the date of diagnosis to the date of death from any cause, with surviving patients censored at the time of last follow-up. PFS was evaluated from the date of diagnosis to the date of disease progression or death from any cause, with patients alive and free of disease progression censored at the time of last follow-up. Survival distributions were estimated using the Kaplan-Meier method, and were compared using the log-rank test. Univariate and multivariable Cox proportional hazards models were fit for OS and PFS using available clinical, biologic, and treatment-related variables. Univariate analysis was performed that included CK and the 11 most common cytogenetic abnormalities. Variables that were found to be significantly associated with survival in the univariate model then were fit in a multivariable model. Abnormalities were subjected to backwards elimination with a P value for removal of .1. Remaining significant variables from the CK/specific abnormality model then were fit into a model with MIPI and Ki-67. For both MIPI and Ki-67, patients with missing data were grouped in an "unknown" category. Treatment site effect was fit as a random effect in multivariable models. The proportional hazards assumption was checked, and significance was assessed at the .05 level. Statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina).
RESULTS

Patient Characteristics
Of 483 MCL cases identified, 18 patients were excluded due to missing survival data, resulting in a sample of 465 patients. Of these, 188 patients did not have karyotypic data available and were excluded from analyses of karyotypic complexity and specific cytogenetic abnormalities. Also excluded were an additional 2 patients who were known to have a CK but for whom no data existed regarding the presence of specific abnormalities. An additional patient only had florescence in situ hybridization results, but no conventional cytogenetic analysis. Patient characteristics for the 274 patients available for analysis with a known karyotype are described in Table 1 . Of these 274 patients, 189 (69%) were male, 20 (7.3%) had (Lugano) stage III disease, 236 (86%) had stage IV disease, and the median age at the time of diagnosis was 63 years (range, 32-83 years). A total of 53 patients (19%) had a CK. Among the 168 patients with an available pretreatment MIPI risk score, 29%, 40%, and 31%, respectively, were considered as being at low, intermediate, and high risk. In the 125 patients with an available Ki-67 proliferative index, Ki-67 was >30% in 47% of patients. Of the 252 patients with known induction data, 48% underwent intensive cytarabine-containing induction. Of 227 patients with known transplantation status, 111 (49%) underwent autologous stem cell transplantation (ASCT) in first remission (CR1). Compared with those patients without CK, patients with CK were more likely to have bone marrow involvement (P<.01), elevated lactate dehydrogenase at the time of diagnosis (P<.01), and a white blood cell count >10,000 (P<.01). In addition, patients with CK were more likely to have a high-risk MIPI score (P<.01). There was no significant difference noted between the CK and non-CK groups with regard to the frequency of intensive induction (54% vs 46%; P 5 .34) or ASCT in CR1 (50% vs 51%; P 5 .88).
The patients without available cytogenetics (188 of 465 patients) were analyzed. In general, the patients with unknown karyotype had a presentation similar to that of those with a non-CK (see Supporting Table 1 ). Specifically, the patients with unknown and non-CKs were similar compared with the patients with CKs with respect to the known prognostic markers of high-risk MIPI (24% and 25% vs 55%, respectively) and high Ki-67 expression (47% and 45% vs 55%). Although the reason for having an unknown karyotype was not known for all patients, the majority had an unknown karyotype due to the test not being ordered at the time of diagnosis, and there were no recorded instances of a failed test.
Predictors of PFS and OS
Patients with a CK had a median OS of 4.5 years compared with 11.6 years for those without a CK (P<.01). The median PFS was 1.9 years in the CK group and 4.4 years in the non-CK group (P<.01). The 2-year OS rate was 68% (95% confidence interval [95% CI], 52%-80%) in the CK group and 91% (95% CI, 85%-94%) in the non-CK group. The 2-year PFS rate was 48% (95% CI, 33%-62%) in the CK group and 76% (95% CI, 69%-82%) in the non-CK group (Fig. 1) .
Of the 465 patients, 228 patients had MIPI data available. The median OS of the high-risk and intermediate-risk MIPI groups was 5.9 years and 8.0 years, respectively, whereas the median OS of the low-risk group was not reached (P 5 .06). The median PFS of the high-risk, intermediate-risk, and low-risk groups was 2.6 years, 3.6 years, and 7.9 years, respectively (P 5 .03).
A total of 125 patients had information available regarding the Ki-67 proliferative index. When we applied a cutoff value of 30%, the median OS was not reached in both the high and low Ki-67 groups (P 5 .21). The 5-year OS rate was 56% (95% CI, 36%-73%) in the high Ki-67 group and 79% (95% CI, 61%-89%) in the low Ki-67 group. The median PFS was 2.4 years in the high Ki-67 group and 4.1 years in the low Ki-67 group (P<.01), with a 5-year PFS rate of 21% (95% CI, 8.2%-37%) in the high Ki-67 group and 44% (95% CI, 27%-60%) in the low Ki-67 group.
Due to the similarities between the patients without cytogenetic data and those with a non-CK, a sensitivity analysis was performed in which those without cytogenetic data (an "unknown karyotype") were included in the non-CK group (see Supporting Fig. 1) . In this sensitivity analysis, CK remained significantly associated with an inferior median OS (4.5 vs 11.6 years; P<.01) and inferior median PFS (1.9 vs 4.2 years; P<.01).
Effect of CK on Survival Stratified by Prognostic Markers
In the 52 patients with high-risk MIPI and cytogenetic data available, the CK and non-CK groups had a median OS of 3.8 years versus not reached, respectively (P 5 .05), and a median PFS of 1.7 years versus 3.8 years, respectively (P 5 .07). In the 67 patients with intermediate-risk MIPI and cytogenetic data available, the CK and non-CK groups had a median OS of 4.7 years versus 11.6 years, respectively (P 5 .21). and a median PFS of 1.6 years versus 3.6 years, respectively (P 5 .03). There were 49 patients with lowrisk MIPI and cytogenetic data. Only 4 of these patients had a CK. There was no clear trend with respect to OS nor PFS given the small number of patients in the CK group.
In 66 patients (8 of whom had a CK) with a Ki-67 proliferative index < 30%, the median OS in the CK versus non-CK groups were 4 years versus not reached, respectively (P<.01). In this group of patients, the median PFS was 1.2 years versus 4.2 years, respectively (P<.01). In 59 patients (11 of whom had a CK) with a Ki-67 proliferative index 30%, the median OS was not reached in either the CK or non-CK groups and no significant difference was seen with regard to either the 1-year, 2-year, or 5-year OS (P 5 .86), but this group of patients had limited follow-up. The median PFS in this same group of patients was 1.5 years versus 2.5 years, respectively (P 5 .11).
PFS was 1.2 years versus 2.9 years in the CK versus non-CK groups, respectively (P<.01).
Among the 117 patients who underwent highintensity cytarabine-containing induction therapy, the median OS in the CK versus non-CK groups was 4.5 versus 11.6 years, respectively (P<.01). In this group of patients, the median PFS was 2.3 years versus 7.8 years, respectively (P<.01). In 127 patients who underwent low-intensity induction therapy, the median OS in the CK group was 3.8 years versus not reached in the non-CK group (P<.01). The median PFS was 1.5 versus 3.1 years in the CK versus non-CK groups, respectively (P<.01).
In 91 patients who underwent high-intensity cytarabine-containing induction followed by ASCT in CR1, CK was associated with poorer OS (5.1 vs 11.6 years; P 5 .04) and PFS (3.6 vs 7.8 years; P<.01) (Fig. 2) .
Effect of Induction Intensity and ASCT in CR1 on Patients Stratified By Karyotypic Complexity
In those patients with a CK, treatment with an intensive cytarabine-containing induction regimen versus a lowintensity regimen had no statistically significant effect on the median OS (4.5 vs 3.8 years; P 5 .77) nor the median PFS (2.3 vs 1.5 years; P 5 .45). Similarly, in those with a CK, ASCT in CR1 did not improve PFS (3.5 vs 1.2 years; P 5 .12) and there was no difference in OS (5.1 vs 4.0 years; P 5 .27). In those patients with a non-CK, significant improvements in PFS were observed with high-intensity cytarabine-containing induction (7.8 vs 3.1 years; P<.01) as well as ASCT in CR1 (6.7 vs 2.9 years; P<.01). However, there was no association noted with OS ( Table 2 ).
The Presence of Specific Cytogenetic Abnormalities Is Not Associated With Survival
In addition to karyotype complexity, the 11 most common specific cytogenetic abnormalities, as seen in Figure  3 , underwent univariate and multivariable analysis with respect to survival.
On univariate analysis, the specific abnormalities associated with inferior PFS were loss(9p), loss(9q), loss(10p), loss(10q), loss(13q), and loss(17p). Inferior OS was associated with loss(9p), loss(9q), and loss(13q). It is interesting to note that on univariate analysis, loss(17p) was associated with inferior PFS (hazard ratio [ , whereas no cytogenetic abnormalities remained in the OS model. It is interesting to note that although loss(17p) was associated with inferior PFS in the univariate model, it was found to not be independently associated with survival when the backward elimination process was applied to the multivariable model.
CK Remains Associated With Survival Independent of MIPI and Ki-67
On multivariable analysis of CK, in addition to the welldescribed prognostic factors of MIPI and Ki-67, CK remained strongly associated with both PFS and OS. MIPI was not found to be independently associated with survival, and Ki-67 was only independently associated with PFS (Table 3) . Only CK, but not any specific cytogenetic abnormalities, was included in the MIPI/Ki-67 OS model due to the fact that no specific abnormality was found to be independently associated with OS. In the CK/MIPI/Ki-67 model, CK was associated with inferior survival (HR, 1.98; 95% CI, 1.12-3.49 [P 5 .02]), whereas MIPI and Ki-67 had no independent association.
Because both loss(9q) and CK remained in the PFS model above, they both were included in the MIPI/Ki-67 PFS model. On multivariable analysis of CK/loss(9q)/ MIPI/Ki-67, CK remained independently associated with PFS (HR, 1.91; 95% CI, 1.17-3.12 [P 5 .01]), as did a Ki-67 proliferative index >30% (HR, 1.86; 95% CI, 1.06-3.28 [P 5 .03]) whereas loss(9q) was not.
DISCUSSION
The initial management of MCL ranges from active observation to high-intensity induction therapy.
14 In addition, postinduction consolidation with ASCT and/or maintenance therapy remains a consideration for patients. Given the broad clinical heterogeneity of MCL, improved characterization of disease behavior is important to define the optimal treatments for individual patients.
The findings of the current study suggest an important role for cytogenetics in the risk stratification of patients with MCL. The results herein demonstrate that a CK was associated with reduced OS (11.6 years vs 4.5 years) and PFS (4.4 years vs 1.9 years) when compared with a non-CK in this large multi-institution population of patients with MCL. These findings appear to apply regardless of the intensity of the induction regimen and whether ASCT is included in the upfront treatment strategy, thereby suggesting that current aggressive therapy approaches do not abrogate the risk associated with the presence of a CK. The poor outcomes in the CK population, despite intensive induction and ASCT in CR1, suggest a need for the development of clinical trials to investigate novel/alternative treatment approaches for this population. The determination of whether certain alternative approaches such as allogeneic transplantation or specific novel agents and combination therapies will be effective in patients with CK will require carefully designed multicenter clinical trials. Patients without a CK appeared to benefit significantly from receipt of an intensive cytarabine-containing regimen and ASCT in CR1, with marked differences noted in PFS but not OS, suggesting that clinical trials investigating cytarabinebased approaches and ASCT in CR1 may benefit by focusing on this population or stratifying by CK.
Compared with prior analyses, the results of the current larger multi-institution study demonstrated that CK but not MIPI score significantly predicted PFS and OS on multivariable analyses. In addition, the presence of a CK was found to be significantly associated with inferior outcomes in both intermediate-risk and high-risk MIPI groups, and patients without a CK had prolonged OS within the high-risk MIPI group, suggesting that cytogenetics may help to distinguish patients within MIPI subgroups. In addition, in patients with a low Ki-67 proliferative index, a CK was found to predict worse outcomes compared with patients with a non-CK. The association between CK and inferior outcomes remained when accounting for specific cytogenetic abnormalities. It is interesting to note that although loss(17p) initially was hypothesized to be a possible driver of the association between presence of a CK and inferior survival, on multivariable modeling only CK, but not loss(17p), was found to be associated with inferior survival. Loss(17p) was significant in the univariate PFS model. It had an elevated HR, but did not meet statistical significance in the univariate OS model. Although surprising, the lack of an association of loss(17p) has been described in multiple other analyses. 10, 12, 13, 15 Espinet et al described loss(17p) as being prognostic in a multivariable model, 9 and Sarkozy et al reported that it was prognostic in univariable but not multivariable modeling. 12 More recently, Eskelund et al used data from the Nordic MCL trials to demonstrate that in patients aged <66 years, TP53 mutations were associated with inferior OS (HR, 6.2; P<.01) and time to disease recurrence (HR, 6.9; P<.01), with a median OS of 1.8 years. 16 In addition, they demonstrated that TP53-mutated cases had an inferior response to intensive induction therapy. Their analysis used an 8-gene next-generation sequencing (NGS) panel compared with the current study, which used metaphase cytogenetics. The differences in sensitivity for single gene mutations using NGS likely contributed to their finding of an association between TP53 mutation and survival whereas the results of the current study did not note this finding using metaphase cytogenetics. In addition, del(17p) may not necessarily suggest a TP53 mutation. As a result, further investigation is required to better understand the relative importance of a TP53 deletion versus mutation. However, both analyses found that genomic aberrations play a more significant role in MCL prognosis compared with the traditional prognostic markers of MIPI and Ki67. 16 Unfortunately, some subgroup analyses were limited due to small sample sizes and unavailable data. Other variables, such as SOX11 expression and blastoid variant histology, also have been shown to have a prognostic impact, 8 but were not evaluated in the current study. It is unknown whether these factors would correlate with karyotypic complexity and/or add to its prognostic impact. In addition, the specific cytogenetic abnormality analysis was considered exploratory, and a multiple comparisons adjustment with respect to outcomes was not used. Given the era in which these patients were treated, minimal residual disease (MRD) was not routinely assessed. As a result, we cannot comment on the impact of a CK on the achievement of an MRD-negative state nor the impact of a CK on response duration for MRD-negative patients.
In clinical practice, it already is possible to use biologic characteristics to evaluate disease phenotype. Although the MIPI score currently uses a combination of patient-related (age and performance status) and laboratory (white blood cell count and lactate dehydrogenase) factors to predict prognosis, the Ki-67 proliferation index provides a prognostic marker that speaks more specifically to tumor biology. Adding to this, the current study data indicate that karyotypic complexity also can be a biologic measure used to predict outcomes until future methods with NGS and gene expression profiling are refined. Already, mutations in genes such as NOTCH1/2 are being correlated with prognosis, and recurrent mutations in ATM, CCND1, TP53, BIRC3, TLR2, and various chromatin modifiers have been identified in patients with MCL by NGS. 17, 18 Future studies hopefully will identify those mutations that are predictive of a CK, and such mutations then could be evaluated prospectively or be used to develop risk-adapted approaches.
Although cytogenetics are not formally a part of the standard workup for MCL, 19, 20 it is not unusual for a cytogenetic assessment to be available, and it can be implemented easily because this is a standard technique for multiple other hematologic malignancies. Because metaphase karyotyping cannot be performed once a diagnostic specimen (such as a lymph node biopsy) is placed in formalin, it is important to ensure that conventional cytogenetic analysis is ordered on fresh lymph node biopsies in patients suspected to have MCL. Fortunately, this analysis is readily available for the majority of patients with newly diagnosed lymphoma and therefore can be implemented easily into clinical practice. The current analysis has identified that a CK independently predicts for a poor prognosis overall in patients with MCL, regardless of additional prognostic markers such as the MIPI score, Ki-67 proliferative index, or specific cytogenetic abnormality. These data indicate that the assessment of a CK provides meaningful prognostic data independent of MIPI and Ki-67 and should be collected in clinical trials and considered for incorporation into clinical practice. Unfortunately, outcomes in patients with MCL with CKs still were relatively poor, even with intensification of induction therapy and ASCT in CR1. As a result, we conclude that the development of novel/alternative approaches for patients with MCL with a CK represents an unmet medical need that can be addressed with future clinical trials. 
FUNDING SUPPORT
